TIP + TIP and placebo + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-cystic Fibrosis Bronchiectasis
Conditions
Non-cystic Fibrosis Bronchiectasis
Trial Timeline
Feb 8, 2017 → Mar 20, 2019
NCT ID
NCT02712983About TIP + TIP and placebo + Placebo
TIP + TIP and placebo + Placebo is a phase 2 stage product being developed by Novartis for Non-cystic Fibrosis Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02712983. Target conditions include Non-cystic Fibrosis Bronchiectasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02712983 | Phase 2 | Completed |
Competing Products
8 competing products in Non-cystic Fibrosis Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 2 | 49 |
| Brensocatib | Insmed | Pre-clinical | 20 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 3 | 74 |
| AP-PA02 | Armata Pharmaceuticals | Phase 2 | 44 |